ArticleFrontiers in public health2026
Determinants of self-monitoring adherence in type 2 diabetes: bridging the gap in patient care.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Self-monitoring of blood glucose (SMBG) is a key component of type 2 diabetes mellitus (T2DM) management; however, adherence to recommended practices remains suboptimal. This study aimed to assess SMBG adherence among patients with T2D attending a tertiary diabetes center in Jordan and to identify factors associated with adherence. Methods: A cross-sectional study was conducted among adults with T2DM attending the National Center for Diabetes, Endocrinology, and Genetics in Amman, Jordan, between November 2022 and January 2023. Demographic and clinical data were obtained from medical records, and SMBG adherence was assessed using a validated Arabic self-reported questionnaire. Descriptive statistics summarized adherence patterns, and multivariable regression analyses were performed to identify factors independently associated with SMBG adherence. Results: Among 805 eligible participants enrolled in the study, 539 (67.0%) reported performing SMBG and were included in the adherence and practice analyses. Of these, 255 (47.3%) met the criteria for adherence to the SMBG recommendations adopted for this study. Adherence was highest among patients treated with oral hypoglycemic agents (55.3%) and lower among those receiving combined oral and insulin therapy (38.9%) or insulin alone (40.0%). SMBG was predominantly symptom-driven, and daily monitoring was uncommon. In adjusted analyses, adherence was significantly lower among patients using combined oral and insulin therapy (OR = 0.393) or insulin alone (OR = 0.425) compared with oral therapy alone. Higher adherence was independently associated with the presence of chronic kidney disease (OR = 1.789) and diabetic neuropathy (OR = 2.691). Perceived usefulness of SMBG emerged as the strongest predictor of adherence (OR = 5.741). Conclusion: Adherence to self-monitoring of blood glucose (SMBG) among patients with type 2 diabetes mellitus was suboptimal and largely symptom-driven. Adherence varied by treatment modality and the presence of diabetes-related complications and was strongly influenced by patients' perceived usefulness of SMBG. Targeted education and individualized SMBG recommendations are needed to improve adherence in routine diabetes care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.